Based on these characteristics, with the aim of proposing potential anti-cancer treatment, Stuart and co-workers described a member of anti-cancer lipoate derivatives, CPI-613, which induces an E3-mediated burst of ROS leading to E2 inactivation in cancer cells [51]. The gene discussed is DLD; the disease is cancer.